Amarin Adds $28M to Support CNS, Cardiovascular Pipeline
Amarin Corp. plc, which rebounded from dismal Huntington's disease data with the December acquisition of Ester Neurosciences Ltd., is moving full steam ahead once again, thanks to a $28 million cash infusion. (BioWorld Today)
Diagnostics & Biotech-Based Treatments Key to Cancer Fight
The continued increase in cancer incidence is resulting in rapid growth in the number of individuals alive with cancer, leading in turn to greater demand for products and services for cancer diagnosis, treatment and monitoring. Read about the biotech and med-tech companies at the forefront of this growth and the products they re banking on.
Intercell Acquiring Iomai for $189M in Cash, Shares
In a move that will add two Phase II development programs to its pipeline, Intercell AG entered an agreement to acquire Gaithersburg, Md.-based Iomai Corp. in a cash-and-shares deal valued, on a fully diluted basis, at approximately $189 million. (BioWorld International)
Lupus Fells Contender, But Endpoint Might Be to Blame
There's an old joke about a man who walks into a talent agency with his dog and tells the agent that the dog can talk. To convince the agent, the man asks the dog what the top of the house is called, and the dog responds, "Roof!" When asked what the outside of the tree is called, the dog says, "Bark," and when asked to name the most famous baseball player in the world, the dog replies, "Ruth!" (BioWorld Financial Watch)
